株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アレルギー性結膜炎:治療薬パイプライン分析および2016年までの市場予測

Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016

発行 GlobalData 商品コード 121276
出版日 ページ情報 英文 39 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
アレルギー性結膜炎:治療薬パイプライン分析および2016年までの市場予測 Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016
出版日: 2010年05月10日 ページ情報: 英文 39 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、アレルギー性結膜炎市場について治療薬パイプライン分析および2016年までの市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争、企業プロファイルを盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 アレルギー性結膜炎市場:市場の特徴

  • 概要
  • 症状
  • 治療
  • 市場規模
  • 市場予測および年複利成長率(CAGR)
  • 市場促進および阻害要因
  • 機会およびアンメットニーズ
  • 要点

第3章 競合のアセスメント

  • 概要
  • 戦略的競合企業の評価
  • 主な市販製品のプロファイル
  • 要点

第4章 パイプラインのアセスメント

  • 概要
  • 戦略的パイプラインの評価
  • 治療:臨床開発中の有望な治療薬
  • 臨床開発中の有望な治療薬の分子プロファイル
  • アレルギー性結膜炎市場:作用機序別臨床パイプライン
  • アレルギー性結膜炎:臨床開発段階別パイプライン
  • 要点

第5章 将来の市場競争についての示唆

第6章 将来の企業

  • イントロダクション
  • Novagali Pharma S.A
  • Fovea Pharmaceuticals SA
  • Cytos Biotechnology AG
  • Ono Pharmaceutical Co. Ltd

第7章 付録

図表

目次
Product Code: GDHCPRT096

Abstract

Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData’s pharmaceutical and healthcare report,” Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016” provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-label formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapies

Scope

The scope of the report includes:
- Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.
- Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global allergic conjunctivitis market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Allergic Conjunctivitis Market : Market Characterization 6
2.1 Disease Overview 6
2.2 Symptoms 7
2.3 Treatment 7
2.3.1 Allergic Conjunctivitis - Major Different Classes of Drug Description 7
2.4 Allergic Conjunctivitis Market Size 8
2.5 Allergic Conjunctivitis Market Forecast and CAGR 8
2.6 Drivers and Barriers for the Allergic Conjunctivitis Market 9
2.6.1 Drivers for the Allergic Conjunctivitis Market 9
2.6.2 Barriers for the Allergic Conjunctivitis Market 10
2.7 Opportunity and Unmet Need 10
2.8 Key Takeaway 11
3 Allergic Conjunctivitis Market : Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profiles of the Major Marketed Products in the Allergic Conjunctivitis Market 13
3.3.1 Bepreve (bepotastine besilate ophthalmic solution) 1.5% 13
3.3.2 Patanol / Opatanol (olopatadine hydrochloride ophthalmic solution) 0.1% 14
3.3.3 Elestat (epinastine HCl ophthalmic solution) 0.05% 14
3.3.4 Alomide (lodoxamide tromethamine) ophthalmic solution 0.1% 15
3.4 Key Takeaway 16
4 Allergic Conjunctivitis Market : Pipeline Assessment 17
4.1 Overview 17
4.2 Strategic Pipeline Assessment 17
4.2.1 Technology Trends Analytic Framework 17
4.3 Allergic Conjunctivitis Therapeutics - Promising Drugs under Clinical Development 18
4.4 Molecule Profile for Promising Drugs under Clinical Development 19
4.4.1 Vekacia (cyclosporine A) 19
4.4.2 FOV1101 (Prednisporin) 20
4.4.3 ONO-6126 20
4.5 Allergic Conjunctivitis Market - Clinical Pipeline by Mechanism of Action 21
4.6 Allergic Conjunctivitis - Pipeline by Clinical Phases of Development 21
4.6.1 Allergic Conjunctivitis Therapeutics - Phase III Clinical Pipeline 22
4.6.2 Allergic Conjunctivitis Therapeutics - Phase II Clinical Pipeline 22
4.6.3 Allergic Conjunctivitis Therapeutics - Phase I Clinical Pipeline 22
4.6.4 Allergic Conjunctivitis Therapeutics - Preclinical Pipeline 23
4.7 Key Takeaway 23
5 Allergic Conjunctivitis Market : Implications for Future Market Competition 24
6 Allergic Conjunctivitis Market : Future Players in the Allergic Conjunctivitis Market 26
6.1 Introduction 26
6.2 Novagali Pharma S.A 26
6.2.1 Company Overview 26
6.2.2 Ophthalmic Portfolio 27
6.2.3 Allergic Conjunctivitis Product Portfolio 27
6.3 Fovea Pharmaceuticals SA 28
6.3.1 Company Overview 28
6.3.2 Ophthalmic Portfolio 29
6.3.3 Allergic Conjunctivitis Product Portfolio 29
6.4 Cytos Biotechnology AG 30
6.4.1 Company Overview 30
6.4.2 Financial Performance 30
6.4.3 Business Description 30
6.4.4 Ophthalmic Portfolio 31
6.4.5 Allergic Conjunctivitis Product Portfolio 31
6.5 Ono Pharmaceutical Co. Ltd 31
6.5.1 Company Overview 31
6.5.2 Financial Performance 31
6.5.3 Business Description 31
6.5.4 Ophthalmic Portfolio 32
6.5.5 Allergic Conjunctivitis Product Portfolio 32
7 Allergic Conjunctivitis Market : Appendix 33
7.1 Market Definitions 33
7.2 Abbreviations 33
7.3 Research Methodology 34
7.3.1 Coverage 34
7.3.2 Secondary Research 35
7.3.3 Forecasting 35
7.3.4 Primary Research 38
7.3.5 Expert Panels 38
7.4 Contact Us 38
7.5 Disclaimer 38
7.6 Sources 39

1.1 List of Tables
Table 1: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2001-2009 8
Table 2: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2009-2016 9
Table 3: Marketed Products Analysis in Allergic Conjunctivitis Market, 2010 16
Table 4: Allergic Conjunctivitis Therapeutics - Most Promising Drugs under Clinical Development, 2010 18
Table 5: Allergic Conjunctivitis Therapeutics - Phase III Clinical Pipeline, 2010 22
Table 6: Allergic Conjunctivitis Therapeutics - Phase II Clinical Pipeline, 2010 22
Table 7: Allergic Conjunctivitis Therapeutics - Phase I Clinical Pipeline, 2010 22
Table 8: Allergic Conjunctivitis Therapeutics - Preclinical Pipeline, 2010 23
Table 9: Novagali Pharma S.A - Marketed Products, 2010 27
Table 10: Novagali Pharma S.A - Pipeline Products, 2010 27
Table 11: Fovea Pharmaceuticals SA - Pipeline Products, 2010 29
Table 12: Cytos Biotechnology AG - Pipeline Products, 2010 31
Table 13: Ono Pharmaceutical Co. Ltd- Pipeline Products, 2010 32

1.2 List of Figures
Figure 1: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2001-2009 8
Figure 2: Global Allergic Conjunctivitis Therapeutics Market, Revenue ($m), 2009-2016 9
Figure 3: Opportunity and Unmet Need in the Allergic Conjunctivitis Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Marketed Products for Allergic Conjunctivitis, 2010 12
Figure 5: Technology Trends Analytic Framework of the Allergic Conjunctivitis Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of the Allergic Conjunctivitis Pipeline - Description, 2010 18
Figure 7: Allergic Conjunctivitis Market - Clinical Pipeline by Mechanism of Action, 2010 21
Figure 8: Allergic Conjunctivitis Pipeline by Phase of Clinical Development, 2010 21
Figure 9: Implications for Future Market Competition in the Allergic Conjunctivitis Market, 2010 24
Figure 10: Allergic Conjunctivitis Market - Clinical Pipeline by Company, 2010 26
Figure 11: GlobalData Methodology 34
Figure 12: GlobalData Market Forecasting Model 37

Back to Top